口服、膀胱内灌注及经皮注射卡介苗治疗浅表性膀胱癌的随机前瞻性比较

A randomized prospective comparison of oral versus intravesical and percutaneous bacillus Calmette-Guerin for superficial bladder cancer.

作者信息

Lamm D L, DeHaven J I, Shriver J, Crispen R, Grau D, Sarosdy M F

机构信息

Department of Urology, West Virginia University Health Sciences Center, Morgantown.

出版信息

J Urol. 1990 Jul;144(1):65-7. doi: 10.1016/s0022-5347(17)39367-9.

DOI:10.1016/s0022-5347(17)39367-9

PMID:2193172

Abstract

Reports of a dramatic decrease in tumor recurrence and regression of muscle invasive disease with oral bacillus Calmette-Guerin prompted us to conduct a randomized prospective comparison of oral bacillus Calmette-Guerin with the standard intravesical plus percutaneous therapy. Oral therapy consisted of 200 mg. Tice bacillus Calmette-Guerin 3 times each week. Intravesical and percutaneous Tice bacillus Calmette-Guerin at a dose of 50 mg. was given weekly for 6 weeks, at 8, 10 and 12 weeks, then at 6 months and every 6 months thereafter. Minimal side effects confirmed the safety of oral bacillus Calmette-Guerin. Tumor recurrence was documented in 21 of 33 oral bacillus Calmette-Guerin patients (64%) and 18 of 55 (33%) who received intravesical plus percutaneous therapy (p less than 0.002, chi-square test). We were unable to demonstrate any antitumor activity of oral bacillus Calmette-Guerin in this study.

摘要

口服卡介苗可使肿瘤复发显著减少且肌肉浸润性疾病消退，相关报告促使我们对口服卡介苗与标准膀胱内加经皮治疗进行随机前瞻性比较。口服治疗方案为每周3次，每次服用200毫克蒂策卡介苗。膀胱内和经皮给予蒂策卡介苗，剂量为50毫克，每周1次，共6周，在第8、10和12周给药，然后在6个月时给药，此后每6个月给药1次。轻微的副作用证实了口服卡介苗的安全性。33例口服卡介苗患者中有21例（64%）出现肿瘤复发，接受膀胱内加经皮治疗的55例患者中有18例（33%）出现肿瘤复发（卡方检验，P<0.002）。在本研究中，我们未能证明口服卡介苗具有任何抗肿瘤活性。